Ledger.Open graph →
SEC Form D · filed January 27, 2022

NextRNA Therapeutics, Inc

Offering
$50.0M
Sold
$23.4M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (30)

Susan A. Langer · Cambridge, MADirectorFred A. Mermelstein · Cambridge, MADirectorDrew A. Dennison · Cambridge, MADirectorMalcolm A. Salter · Cambridge, MADirectorCarl A. Novina · Cambridge, MADirectorElena A. Prokupets · Cambridge, MADirectorBarry A. Polisky · Cambridge, MADirectorAndrea A. Armstrong · Cambridge, MADirectorArthur A. Becker · Cambridge, MADirectorDominique A. Verhelle · Cambridge, MADirectorMarc A. Cohen · Boston, MAExec · DirectorChristine A. Henderson · Cambridge, MADirectorKenneth A. Anderson · Cambridge, MADirectorJulia A. Novina · Cambridge, MAExecAlain A. Cohen · Cambridge, MADirectorCarl A. Novina · Cambridge, MADirectorElena A. Prokupets · Cambridge, MADirectorBarry A. Polisky · Cambridge, MADirectorAndrea A. Armstrong · Cambridge, MADirectorArthur A. Becker · Cambridge, MADirectorDominique A. Verhelle · Cambridge, MADirectorMarc A. Cohen · Boston, MAExec · DirectorChristine A. Henderson · Cambridge, MADirectorSusan A. Langer · Cambridge, MADirectorFred A. Mermelstein · Cambridge, MADirectorKenneth A. Anderson · Cambridge, MADirectorDrew A. Dennison · Cambridge, MADirectorMalcolm A. Salter · Cambridge, MADirectorJulia A. Novina · Cambridge, MAExecAlain A. Cohen · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗